2023
Positron Emission Tomography Imaging of Vessel Wall Matrix Metalloproteinase Activity in Abdominal Aortic Aneurysm
Toczek J, Gona K, Liu Y, Ahmad A, Ghim M, Ojha D, Kukreja G, Salarian M, Luehmann H, Heo G, Guzman R, Chaar C, Tellides G, Hassab A, Ye Y, Shoghi K, Zayed M, Gropler R, Sadeghi M. Positron Emission Tomography Imaging of Vessel Wall Matrix Metalloproteinase Activity in Abdominal Aortic Aneurysm. Circulation Cardiovascular Imaging 2023, 16: e014615. PMID: 36649454, PMCID: PMC9858355, DOI: 10.1161/circimaging.122.014615.Peer-Reviewed Original ResearchConceptsAbdominal aortic aneurysmHuman aortic tissueMMP activityAortic tissueAortic aneurysmMMP inhibitorsMurine modelMatrix metalloproteinasesPositron emission tomography/Toxicology studiesAortic MMP activityPositron emission tomography radioligandAngiotensin II infusionEmission tomography/Murine abdominal aortic aneurysmsBroad-spectrum MMP inhibitorMatrix metalloproteinase activityPositron emission tomography (PET) tracerPositron emission tomography (PET) imagingEmission Tomography ImagingPositron emission tomographyEmission tomography tracerII infusionRisk stratificationTomography/
2019
Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h
Kobayashi K, Manabe O, Hirata K, Yamaguchi S, Kobayashi H, Terasaka S, Toyonaga T, Furuya S, Magota K, Kuge Y, Kudo K, Shiga T, Tamaki N. Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 47: 1833-1842. PMID: 31781832, DOI: 10.1007/s00259-019-04626-8.Peer-Reviewed Original ResearchConceptsStandardized uptake valueWhite matter ratioWhite matterGray matterMean standardized uptake valueMethodsTwenty-three patientsScan time pointsPositron emission tomography (PET) tracerEmission tomography tracerMaximum tumorIntravenous injectionResultsAt 2Single injectionBrain tumorsUptake valueBrain tissueTumor hypoxiaTumorsTomography tracerTime pointsHypoxia imagingNormal ratioHypoxic tumorsPatientsSUVmaxA single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
Finnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas J, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE. A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60: 958-967. PMID: 30924924, PMCID: PMC6532410, DOI: 10.1111/epi.14701.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticonvulsantsCarbon RadioisotopesFemaleHealthy VolunteersHumansInhibitory Concentration 50Injections, IntravenousLevetiracetamMagnetic Resonance ImagingMaleMembrane GlycoproteinsNerve Tissue ProteinsNeuroimagingPositron-Emission TomographyProtein BindingPyrrolidinonesConceptsSynaptic vesicle glycoprotein 2AIntravenous brivaracetamHours postdoseBrain penetrationHealthy volunteersDaily oral dosingPositron emission tomography studyFurther clinical studiesEmission tomography studiesPlasma concentration relationshipPositron emission tomography (PET) tracerEmission tomography tracerVivo animal studiesAcute seizuresAntiepileptic drugsTherapeutic dosesCohort 2Oral dosingCohort 1Clinical studiesCohort 3LevetiracetamAnimal studiesRelevant dosesBrivaracetam
2018
In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents
Boutagy NE, Wu J, Cai Z, Zhang W, Booth CJ, Kyriakides TC, Pfau D, Mulnix T, Liu Z, Miller EJ, Young LH, Carson RE, Huang Y, Liu C, Sinusas AJ. In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents. JACC Basic To Translational Science 2018, 3: 378-390. PMID: 30062224, PMCID: PMC6058999, DOI: 10.1016/j.jacbts.2018.02.003.Peer-Reviewed Original ResearchLeft ventricular ejection fractionSuperoxide productionReactive oxygen speciesMarkers of ROSNovel positron emission tomography (PET) tracerEarly detectionMyocardial superoxide productionVentricular ejection fractionDoxorubicin-induced cardiotoxicityCardiac superoxide productionPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerEjection fractionCancer patientsCardiotoxicity detectionEmission tomographyTomography tracerCardiotoxicityReactive oxygen species (ROS) detectionWeeksOxygen speciesRodentsEchocardiographyPatients
2016
18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis
Manabe O, Hirata K, Shozo O, Shiga T, Uchiyama Y, Kobayashi K, Watanabe S, Toyonaga T, Kikuchi H, Oyama-Manabe N, Tamaki N. 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. Journal Of Nuclear Cardiology 2016, 24: 329-331. PMID: 27071998, DOI: 10.1007/s12350-016-0495-2.Peer-Reviewed Original ResearchConceptsCardiac sarcoidosisF-fluoromisonidazolePositron emission tomography (PET) tracerEmission tomography tracerFMISO uptakeHypoxic tissueTomography tracerSarcoidosis18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 43: 1469-1476. PMID: 26841941, DOI: 10.1007/s00259-016-3320-x.Peer-Reviewed Original ResearchConceptsPresence of necrosisBrain tumorsFMISO PETFMISO uptakeSevere hypoxiaFMISO PET/Brain tumor patientsPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerHistopathological necrosisPathological necrosisPoor prognosisSurgical strategyIntratumoral necrosisNeuroepithelial tumorsTumor resectionPathological diagnosisTumor patientsCerebellum ratioTreatment decisionsMethodsThis studyGroup 2Group 1Experienced neuropathologistIn vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB
DeLorenzo C, Gallezot JD, Gardus J, Yang J, Planeta B, Nabulsi N, Ogden RT, Labaree DC, Huang YH, Mann JJ, Gasparini F, Lin X, Javitch JA, Parsey RV, Carson RE, Esterlis I. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB. Cerebrovascular And Brain Metabolism Reviews 2016, 37: 2716-2727. PMID: 27742888, PMCID: PMC5536783, DOI: 10.1177/0271678x16673646.Peer-Reviewed Original ResearchConceptsMetabotropic glutamate receptor subtype 5Test-retest studySubtype 5Absolute test-retest variabilityBrain glutamatergic systemSame dayPositron emission tomography (PET) tracerTest-retest variabilityEmission tomography tracerGlutamatergic systemLarge cohortSmall cohortStudy designTomography tracerMGluR5ScansCohortVivo variationsDaysReplication studyBinding increasesResidual radioactivitySubjectsBinding differences
2009
High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943
Nabulsi N, Huang Y, Weinzimmer D, Ropchan J, Frost JJ, McCarthy T, Carson RE, Ding YS. High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943. Nuclear Medicine And Biology 2009, 37: 205-214. PMID: 20152720, PMCID: PMC3780362, DOI: 10.1016/j.nucmedbio.2009.10.007.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply